Perceptive Advisors’s ACELYRIN SLRN Stock Holding History

Perceptive Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,000	Closed	-$2.03M	–	114
2023 Q3	$2.03M	Hold	200,000	–	–	0.07%	84
2023 Q2	$4.18M	Buy	+200,000	New	+$4.09M	0.12%	77

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors's SLRN Position: Q4 2023 in Review

Perceptive Advisors sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 200,000 shares — an estimated $2.03M sold.

Perceptive Advisors first reported a position in SLRN in Q2 2023 and held it in 2 quarters. The position peaked at $4.18M in Q2 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Perceptive Advisors reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Perceptive Advisors sold 200,000 ACELYRIN shares in Q4 2023, an estimated $2.03M.
Perceptive Advisors first reported a position in ACELYRIN in Q2 2023 and held it in 2 quarters.
Perceptive Advisors's ACELYRIN position peaked at $4.18M in Q2 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.